‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Image: MarketWatch
ad slot · in-content video 16:9
Coverage
Coverage
- The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.